Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes

NCT00612040 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00612040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00612040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
June 30, 2008
Enrollment
178 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 1